Market News & Trends
Nevakar Announces First Subject Dosed in its Phase 3 Clinical Trial
Nevakar, LLC recently announced that the first subject has been dosed in a Phase 3 clinical trial of NVK-002, the company's investigational, topical ophthalmic solution…
Ablynx’s Phase III HERCULES Study Selected for Oral Presentation
Ablynx NV announced that results from its Phase III HERCULES study of caplacizumab have been selected as one of only six abstracts for oral presentation…
Lead Pharma Achieves Third Milestone in Sanofi Collaboration
Lead Pharma recently announced it has achieved a third milestone under its research collaboration with Sanofi, triggering an undisclosed milestone payment. The collaboration aims to…
Immunovaccine & Leidos Expand Collaboration
Immunovaccine Inc. recently announced it is expanding its collaboration with Leidos to develop preventative, peptide-based malaria vaccine candidates. The US Agency for International Development (USAID)…
TESARO Secures $500-Million Financing
TESARO, Inc. recently announced it has entered into a definitive term loan agreement with BIOPHARMA CREDIT PLC and BIOPHARMA CREDIT INVESTMENTS IV SUB LP, investment…
CrownBio’s Translatable FATZO Model Utilized in Eli Lilly’s Research Programs
Crown Bioscience recently announced the publication of two new papers illustrating the utility of Crown Bioscience’s proprietary FATZO model as a model for obesity and…
Flexicare Acquires Medisize B.V.
Flexicare (Group) Limited, a leading UK headquartered manufacturer of medical devices, recently announced it has acquired Medisize B.V. from an affiliate of Phillips-Medisize, LLC. …
Quotient Sciences Acquires Pharmaterials, Launches as New Global Identity for Quotient Clinical
Quotient Sciences, the drug development services organization, recently announced it has acquired Pharmaterials, a contract development and manufacturing organization (CDMO) based in Reading, UK. The…
Aytu BioScience Receives Market Approval for the MiOXSYS System for Male Infertility
Aytu BioScience, Inc. recently announced that the Australian Government Department of Health and Therapeutic Goods Administration (TGA) has approved the MiOXSYS System for inclusion on…
BriaCell Provides Clinical Update on its Lead Vaccine Candidate
BriaCell Therapeutics Corp. recently released a clinical update on its ongoing Phase I/IIa study of its lead vaccine candidate, BriaVax, in advanced breast cancer patients.…
SOTIO Completes Enrolment of Phase III VIABLE Study
SOTIO, a biotechnology company owned by the PPF Group, recently announced the enrolment of the last patient into the VIABLE study, a global Phase III…
West Announces Official Opening of Expanded Kiefernweg Campus & New Center of Excellence for Innovation & Technology
West Pharmaceutical Services, Inc., a global leader in innovative solutions for injectable drug administration, officially opened the Company’s recently expanded Kiefernweg Campus in Eschweiler, Germany,…
SIO-ADM & Gattefossé Announce Partnership
Gattefossé USA and Gattefossé Canada recently announce their partnership with Société Industrielle des Oléagineux (SIO), a subsidiary of Archer Daniels Midland Company (ADM), to bring…
G1 Therapeutics Announces Publication in Cancer Discovery
G1 Therapeutics, Inc. recently announced the publication CDK4/6 Inhibition Augments Anti-Tumor Immunity by Enhancing T Cell Activation, is available online in the journal Cancer Discovery.…
Organovo & Viscient Biosciences Collaborate to Develop Custom Research Platform
Organovo Holdings, Inc. and Viscient Biosciences recently announced a collaboration to develop a custom research platform for studying liver disease. The partnership is expected to…
Citoxlab Acquires American CRO Xenometrics
Citoxlab Group recently announced the acquisition of Xenometrics, an American CRO specialized in the non-clinical assessment of new drug candidates. This acquisition is the third…
Sarepta Therapeutics Signs Exclusive Global Collaboration
Sarepta Therapeutics, Inc. recently announced it has signed a research collaboration agreement with Duke University, granting the company an option to an exclusive license to…
Rhythm Announces Preliminary Data from Phase 2 Study of Setmelanotide for Treatment of Bardet-Biedl Syndrome
Rhythm Pharmaceuticals, Inc. recently announced the presentation of preliminary data from an ongoing Phase 2 proof-of-concept study evaluating the safety and efficacy of setmelanotide, the…
Novoteris Investigator Receives Health Canada Clearance to Start Phase 2a Clinical Trial
Novoteris, LLC recently announced that the Therapeutic Products Directorate of Health Canada has cleared an investigator sponsored, pilot clinical trial application exploring the treatment of…
Arcturus Therapeutics & Synthetic Genomics Announce Strategic Alliance
Arcturus Therapeutics, Inc. and Synthetic Genomics, Inc. recently announced they have entered into a research collaboration and worldwide license agreement to develop self-amplifying RNA-based vaccines…
